Navigation Links
Immtech Investor Conference Call Scheduled for February 22, 2008
Date:2/19/2008

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) will have an investor conference call on February 22, 2008, at 4.30PM (ET) to present an update on the Company. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. The User Access Code is # 36251882. To register, please call no later than 10 minutes prior to the scheduled start of the call. A recording of the conference call will be available on the Company's website (http://www.immtechpharma.com) from February 23, 2008 to March 14, 2008.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. ("Immtech") is a pharmaceutical company working to commercialize drugs to treat infectious diseases and is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit Immtech's website at http://www.immtechpharma.com.

This press release contains forward-looking statements regarding Immtech's business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) Immtech's dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at reasonable costs; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and Immtech undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Immtech Completes Malaria Prevention Trial
4. MDS to Provide Financial Guidance at 2008 Annual Investor Day
5. Investor Insight Initiates Analyst Coverage on Crdentia
6. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
7. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
8. MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc.
9. Assurant President and Chief Executive Officer Robert B. Pollock to Present at Merrill Lynch Insurance Investor Conference on February 12
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Torchmark Corporation to Present at Merrill Lynch Insurance Investors Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
Breaking Medicine Technology: